Branden R. Sosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Branden R. Sosa has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Blake Greenblatt
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, USA
6 shared publications - Mathias P. G. Bostrom
Hospital for Special Surgery, New York, NY
5 shared publications - Lionel B. Ivashkiv
HSS Research Institute and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, USA
4 shared publications - Xu Yang
Skeletal Health and Orthopedic Research Program, Hospital for Special Surgery, New York, NY, USA.
4 shared publications - Yingzhen Niu
Department of Orthopaedic Surgery, Third Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
3 shared publications - Emile-Victor Kuyl
Department of Orthopaedic Surgery, School of Medicine and Health Sciences, George Washington University, Washington
2 shared publications
Latest Publications
- Open Access
- 20 May 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Open
- Vol. 7 (5) , 674-681
Femoral derotational osteotomies for version abnormalities: a mean ten-year follow-up
Aims: This study aimed to characterize long-term patient-reported outcomes and survivorship following femoral derotational osteotomy (FDO). Methods: A total of 77 hips (60 patients) between March 1997 and February 2019 who underwent FDO using an antegrade intramedullary device for excessive femoral anteversion or retroversion by a single-surgeon were retrospectively reviewed. Those with minimum five-year follow-up, with a mean of ten years (5.2 to 26.8), were included. Pre/postoperative modified Harris Hip Score (mHHS), postoperative patient global impression of change (PGIC), and patient acceptable symptomatic state (PASS) responses were collected. Survivorship free of conversion to arthroplasty was determined. Results: Overall, 90.0% of patients were female with a mean age of 29.6 years (14.4 to 60.9). A total of 52 hips had excessive anteversion with mean deformity of 38.3° (22° to 58°) and mean correction of 22.4° (15° to 40°); 25 hips had excessive retroversion with mean deformity of -8.7° (-24° to 2°) and mean correction of 21.7° (15° to 35°). Concomitant procedures included hip arthroscopy (32.5% of cases), periacetabular osteotomy (9.0%), and tibial derotational osteotomy (7.8%). Regardless of deformity, mean mHHS significantly improved (61.6 to 89.7, p < 0.001). The proportion of minimal clinically important difference (MCID), substantial clinical benefit (SCB), and PASS achievement was 94% (72 of 77), 84% (65 of 77), and 87% (67 of 77), respectively. For PGIC, 95.2% reported improvement, including 88.7% who reported themselves ‘very much improved’ or ‘much improved’. Overall, 92.7% of anteverted and 85.7% of retroverted patients found their current symptomatic state satisfactory (p = 0.398). Three hips (two patients) underwent arthroplasty at mean 4.3 years. Survivorship free from conversion to arthroplasty was 95% at ten, 15, and 20 years. Conclusion: In appropriately selected patients, FDO for hip pain related to excessive femoral anteversion or retroversion provides significant improvements in pain and function at a mean ten-year follow-up. Most patients report postoperative improvement and find their current symptomatic state satisfactory. The procedure effectively preserves the native hip joint with 95% long-term survivorship free of conversion to arthroplasty. Cite this article: Bone Jt Open 2026;7(5):674–681.
- 20 May 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Open
- Vol. 7 (5) , 674-681
Open AccessFemoral derotational osteotomies for version abnormalities: a mean ten-year follow-up
Aims: This study aimed to characterize long-term patient-reported outcomes and survivorship following femoral derotational osteotomy (FDO). Methods: A total of 77 hips (60 patients) between March 1997 and February 2019 who underwent FDO using an antegrade intramedullary device for excessive femoral anteversion or retroversion by a single-surgeon were retrospectively reviewed. Those with minimum five-year follow-up, with a mean of ten years (5.2 to 26.8), were included. Pre/postoperative modified Harris Hip Score (mHHS), postoperative patient global impression of change (PGIC), and patient acceptable symptomatic state (PASS) responses were collected. Survivorship free of conversion to arthroplasty was determined. Results: Overall, 90.0% of patients were female with a mean age of 29.6 years (14.4 to 60.9). A total of 52 hips had excessive anteversion with mean deformity of 38.3° (22° to 58°) and mean correction of 22.4° (15° to 40°); 25 hips had excessive retroversion with mean deformity of -8.7° (-24° to 2°) and mean correction of 21.7° (15° to 35°). Concomitant procedures included hip arthroscopy (32.5% of cases), periacetabular osteotomy (9.0%), and tibial derotational osteotomy (7.8%). Regardless of deformity, mean mHHS significantly improved (61.6 to 89.7, p < 0.001). The proportion of minimal clinically important difference (MCID), substantial clinical benefit (SCB), and PASS achievement was 94% (72 of 77), 84% (65 of 77), and 87% (67 of 77), respectively. For PGIC, 95.2% reported improvement, including 88.7% who reported themselves ‘very much improved’ or ‘much improved’. Overall, 92.7% of anteverted and 85.7% of retroverted patients found their current symptomatic state satisfactory (p = 0.398). Three hips (two patients) underwent arthroplasty at mean 4.3 years. Survivorship free from conversion to arthroplasty was 95% at ten, 15, and 20 years. Conclusion: In appropriately selected patients, FDO for hip pain related to excessive femoral anteversion or retroversion provides significant improvements in pain and function at a mean ten-year follow-up. Most patients report postoperative improvement and find their current symptomatic state satisfactory. The procedure effectively preserves the native hip joint with 95% long-term survivorship free of conversion to arthroplasty. Cite this article: Bone Jt Open 2026;7(5):674–681.
- 18 December 2024
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 107 (4) , 418-426
Skeletal Stem Cells: A Basis for Orthopaedic Pathology and Tissue Repair
➢ Skeletal stem cells (SSCs) continually replenish mature cell populations to support skeletal homeostasis. ➢ SSCs repopulate by self-renewal, have multilineage potential, and are long-lived in vivo. ➢ SSCs express specific combinations of cell surface markers that reflect their lineage identity. ➢ SSCs adapt to their anatomic environment to support regional differences in skeletal behavior and pathology.
- 18 December 2024
- Published by Wolters Kluwer Health in Journal of Bone and Joint Surgery
- Vol. 107 (4) , 418-426
Skeletal Stem Cells: A Basis for Orthopaedic Pathology and Tissue Repair
➢ Skeletal stem cells (SSCs) continually replenish mature cell populations to support skeletal homeostasis. ➢ SSCs repopulate by self-renewal, have multilineage potential, and are long-lived in vivo. ➢ SSCs express specific combinations of cell surface markers that reflect their lineage identity. ➢ SSCs adapt to their anatomic environment to support regional differences in skeletal behavior and pathology.
- Open Access
- 4 November 2024
- Published by MDPI AG in Biomimetics
- Vol. 9 (11) , 673
A Murine Model of Non-Wear-Particle-Induced Aseptic Loosening
Background: The current murine models of peri-implant osseointegration failure are associated with wear particles. However, the current clinical osseointegration failure is not associated with wear particles. Here, we develop a murine model of osseointegration failure not associated with wear particles and validate it by comparing the cellular composition of interfacial tissues with human samples collected during total joint arthroplasty revision for aseptic loosening. Materials and Methods: Thirty-two 16-week-old female C57BL/6 mice underwent implantation with a press-fitted roughened titanium implant (Control, n = 11) to induce normal osseointegration and a press-fitted smooth polymethylmethacrylate implant (PMMA, n = 11), a loosely fitted smooth titanium implant (Smooth-Ti, n = 5) or a loosely fitted roughened titanium implant (Overdrill, n = 5) to induce osseointegration failure. Pullout testing was used to determine the strength of the bone–implant interface (n = 6 of each for Control and PMMA groups) at 2 weeks after implantation. Histology (n = 2/group) and immunofluorescence (n = 3/group) were used to determine the cellular composition of bone–implant interfacial tissue, and this was compared with two human samples. Results: Osseointegration failure was confirmed with grossly loosening implants and the presence of fibrous tissue identified via histology. The maximum pullout load in the PMMA group was 87% lower than in the Control group (2.8 ± 0.6 N vs. 21 ± 1.5 N, p < 0.001). With immunofluorescence, abundant fibroblasts (PDGFRα+ TCF4+ and PDGFRα+ Pu1+) were observed in osseointegration failure groups and the human samples, but not in controls. Interestingly, CD146+PDGFRα+ and LepR+PDGFRα+ mesenchymal progenitors, osteoblasts (OPN+), vascular endothelium (EMCN+) cells were observed in all groups, indicating dynamic osteogenic activity. Macrophages, only M2, were observed in conditions producing fibrous tissue. Conclusions: In this newly developed non-wear-particle-related murine osseointegration failure model, the cellular composition of human and murine interfacial tissue implicates specific populations of fibroblasts in fibrous tissue formation and implies that these cells may derive from mesenchymal stem cells.
- 4 November 2024
- Published by MDPI AG in Biomimetics
- Vol. 9 (11) , 673
Open AccessA Murine Model of Non-Wear-Particle-Induced Aseptic Loosening
Background: The current murine models of peri-implant osseointegration failure are associated with wear particles. However, the current clinical osseointegration failure is not associated with wear particles. Here, we develop a murine model of osseointegration failure not associated with wear particles and validate it by comparing the cellular composition of interfacial tissues with human samples collected during total joint arthroplasty revision for aseptic loosening. Materials and Methods: Thirty-two 16-week-old female C57BL/6 mice underwent implantation with a press-fitted roughened titanium implant (Control, n = 11) to induce normal osseointegration and a press-fitted smooth polymethylmethacrylate implant (PMMA, n = 11), a loosely fitted smooth titanium implant (Smooth-Ti, n = 5) or a loosely fitted roughened titanium implant (Overdrill, n = 5) to induce osseointegration failure. Pullout testing was used to determine the strength of the bone–implant interface (n = 6 of each for Control and PMMA groups) at 2 weeks after implantation. Histology (n = 2/group) and immunofluorescence (n = 3/group) were used to determine the cellular composition of bone–implant interfacial tissue, and this was compared with two human samples. Results: Osseointegration failure was confirmed with grossly loosening implants and the presence of fibrous tissue identified via histology. The maximum pullout load in the PMMA group was 87% lower than in the Control group (2.8 ± 0.6 N vs. 21 ± 1.5 N, p < 0.001). With immunofluorescence, abundant fibroblasts (PDGFRα+ TCF4+ and PDGFRα+ Pu1+) were observed in osseointegration failure groups and the human samples, but not in controls. Interestingly, CD146+PDGFRα+ and LepR+PDGFRα+ mesenchymal progenitors, osteoblasts (OPN+), vascular endothelium (EMCN+) cells were observed in all groups, indicating dynamic osteogenic activity. Macrophages, only M2, were observed in conditions producing fibrous tissue. Conclusions: In this newly developed non-wear-particle-related murine osseointegration failure model, the cellular composition of human and murine interfacial tissue implicates specific populations of fibroblasts in fibrous tissue formation and implies that these cells may derive from mesenchymal stem cells.
- Open Access
- 4 January 2024
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 39 (2) , 106-115
The performance of artificial intelligence chatbot large language models to address skeletal biology and bone health queries
Artificial intelligence (AI) chatbots utilizing large language models (LLMs) have recently garnered significant interest due to their ability to generate humanlike responses to user inquiries in an interactive dialog format. While these models are being increasingly utilized to obtain medical information by patients, scientific and medical providers, and trainees to address biomedical questions, their performance may vary from field to field. The opportunities and risks these chatbots pose to the widespread understanding of skeletal health and science are unknown. Here we assess the performance of 3 high-profile LLM chatbots, Chat Generative Pre-Trained Transformer (ChatGPT) 4.0, BingAI, and Bard, to address 30 questions in 3 categories: basic and translational skeletal biology, clinical practitioner management of skeletal disorders, and patient queries to assess the accuracy and quality of the responses. Thirty questions in each of these categories were posed, and responses were independently graded for their degree of accuracy by four reviewers. While each of the chatbots was often able to provide relevant information about skeletal disorders, the quality and relevance of these responses varied widely, and ChatGPT 4.0 had the highest overall median score in each of the categories. Each of these chatbots displayed distinct limitations that included inconsistent, incomplete, or irrelevant responses, inappropriate utilization of lay sources in a professional context, a failure to take patient demographics or clinical context into account when providing recommendations, and an inability to consistently identify areas of uncertainty in the relevant literature. Careful consideration of both the opportunities and risks of current AI chatbots is needed to formulate guidelines for best practices for their use as source of information about skeletal health and biology.
- 4 January 2024
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 39 (2) , 106-115
Open AccessThe performance of artificial intelligence chatbot large language models to address skeletal biology and bone health queries
Artificial intelligence (AI) chatbots utilizing large language models (LLMs) have recently garnered significant interest due to their ability to generate humanlike responses to user inquiries in an interactive dialog format. While these models are being increasingly utilized to obtain medical information by patients, scientific and medical providers, and trainees to address biomedical questions, their performance may vary from field to field. The opportunities and risks these chatbots pose to the widespread understanding of skeletal health and science are unknown. Here we assess the performance of 3 high-profile LLM chatbots, Chat Generative Pre-Trained Transformer (ChatGPT) 4.0, BingAI, and Bard, to address 30 questions in 3 categories: basic and translational skeletal biology, clinical practitioner management of skeletal disorders, and patient queries to assess the accuracy and quality of the responses. Thirty questions in each of these categories were posed, and responses were independently graded for their degree of accuracy by four reviewers. While each of the chatbots was often able to provide relevant information about skeletal disorders, the quality and relevance of these responses varied widely, and ChatGPT 4.0 had the highest overall median score in each of the categories. Each of these chatbots displayed distinct limitations that included inconsistent, incomplete, or irrelevant responses, inappropriate utilization of lay sources in a professional context, a failure to take patient demographics or clinical context into account when providing recommendations, and an inability to consistently identify areas of uncertainty in the relevant literature. Careful consideration of both the opportunities and risks of current AI chatbots is needed to formulate guidelines for best practices for their use as source of information about skeletal health and biology.
- 20 September 2023
- Published by Springer Nature in Nature
- Vol. 621 (7980) , 804-812
A multi-stem cell basis for craniosynostosis and calvarial mineralization
Craniosynostosis is a group of disorders of premature calvarial suture fusion. The identity of the calvarial stem cells (CSCs) that produce fusion-driving osteoblasts in craniosynostosis remains poorly understood. Here we show that both physiologic calvarial mineralization and pathologic calvarial fusion in craniosynostosis reflect the interaction of two separate stem cell lineages; a previously identified cathepsin K (CTSK) lineage CSC1 (CTSK+ CSC) and a separate discoidin domain-containing receptor 2 (DDR2) lineage stem cell (DDR2+ CSC) that we identified in this study. Deletion of Twist1, a gene associated with craniosynostosis in humans2,3, solely in CTSK+ CSCs is sufficient to drive craniosynostosis in mice, but the sites that are destined to fuse exhibit an unexpected depletion of CTSK+ CSCs and a corresponding expansion of DDR2+ CSCs, with DDR2+ CSC expansion being a direct maladaptive response to CTSK+ CSC depletion. DDR2+ CSCs display full stemness features, and our results establish the presence of two distinct stem cell lineages in the sutures, with both populations contributing to physiologic calvarial mineralization. DDR2+ CSCs mediate a distinct form of endochondral ossification without the typical haematopoietic marrow formation. Implantation of DDR2+ CSCs into suture sites is sufficient to induce fusion, and this phenotype was prevented by co-transplantation of CTSK+ CSCs. Finally, the human counterparts of DDR2+ CSCs and CTSK+ CSCs display conserved functional properties in xenograft assays. The interaction between these two stem cell populations provides a new biologic interface for the modulation of calvarial mineralization and suture patency.
- 20 September 2023
- Published by Springer Nature in Nature
- Vol. 621 (7980) , 804-812
A multi-stem cell basis for craniosynostosis and calvarial mineralization
Craniosynostosis is a group of disorders of premature calvarial suture fusion. The identity of the calvarial stem cells (CSCs) that produce fusion-driving osteoblasts in craniosynostosis remains poorly understood. Here we show that both physiologic calvarial mineralization and pathologic calvarial fusion in craniosynostosis reflect the interaction of two separate stem cell lineages; a previously identified cathepsin K (CTSK) lineage CSC1 (CTSK+ CSC) and a separate discoidin domain-containing receptor 2 (DDR2) lineage stem cell (DDR2+ CSC) that we identified in this study. Deletion of Twist1, a gene associated with craniosynostosis in humans2,3, solely in CTSK+ CSCs is sufficient to drive craniosynostosis in mice, but the sites that are destined to fuse exhibit an unexpected depletion of CTSK+ CSCs and a corresponding expansion of DDR2+ CSCs, with DDR2+ CSC expansion being a direct maladaptive response to CTSK+ CSC depletion. DDR2+ CSCs display full stemness features, and our results establish the presence of two distinct stem cell lineages in the sutures, with both populations contributing to physiologic calvarial mineralization. DDR2+ CSCs mediate a distinct form of endochondral ossification without the typical haematopoietic marrow formation. Implantation of DDR2+ CSCs into suture sites is sufficient to induce fusion, and this phenotype was prevented by co-transplantation of CTSK+ CSCs. Finally, the human counterparts of DDR2+ CSCs and CTSK+ CSCs display conserved functional properties in xenograft assays. The interaction between these two stem cell populations provides a new biologic interface for the modulation of calvarial mineralization and suture patency.
- 16 June 2023
- Published by Springer Nature
- p. 243-254
Trochanter-Osteotomie
- 21 June 2022
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 37 (12) , 2473-2479.e1
Characterization and Potential Relevance of Randomized Controlled Trial Patient Populations in Total Joint Arthroplasty in the United States: A Systematic Review
- 21 June 2022
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 37 (12) , 2473-2479.e1
Characterization and Potential Relevance of Randomized Controlled Trial Patient Populations in Total Joint Arthroplasty in the United States: A Systematic Review
- Open Access
- 1 May 2022
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 11 (5) , 260-269
Intermittent parathyroid hormone increases stability and improves osseointegration of initially unstable implants
Aims: To develop an early implant instability murine model and explore the use of intermittent parathyroid hormone (iPTH) treatment for initially unstable implants. Methods: 3D-printed titanium implants were inserted into an oversized drill-hole in the tibiae of C57Bl/6 mice (n = 54). After implantation, the mice were randomly divided into three treatment groups (phosphate buffered saline (PBS)-control, iPTH, and delayed iPTH). Radiological analysis, micro-CT (µCT), and biomechanical pull-out testing were performed to assess implant loosening, bone formation, and osseointegration. Peri-implant tissue formation and cellular composition were evaluated by histology. Results: iPTH reduced radiological signs of loosening and led to an increase in peri-implant bone formation over the course of four weeks (timepoints: one week, two weeks, and four weeks). Observational histological analysis shows that iPTH prohibits the progression of fibrosis. Delaying iPTH treatment until after onset of peri-implant fibrosis still resulted in enhanced osseointegration and implant stability. Despite initial instability, iPTH increased the mean pull-out strength of the implant from 8.41 N (SD 8.15) in the PBS-control group to 21.49 N (SD 10.45) and 23.68 N (SD 8.99) in the immediate and delayed iPTH groups, respectively. Immediate and delayed iPTH increased mean peri-implant bone volume fraction (BV/TV) to 0.46 (SD 0.07) and 0.34 (SD 0.10), respectively, compared to PBS-control mean BV/TV of 0.23 (SD 0.03) (PBS-control vs immediate iPTH, p < 0.001; PBS-control vs delayed iPTH, p = 0.048; immediate iPTH vs delayed iPTH, p = 0.111). Conclusion: iPTH treatment mediated successful osseointegration and increased bone mechanical strength, despite initial implant instability. Clinically, this suggests that initially unstable implants may be osseointegrated with iPTH treatment. Cite this article: Bone Joint Res 2022;11(5):260–269.
- 1 May 2022
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Research
- Vol. 11 (5) , 260-269
Open AccessIntermittent parathyroid hormone increases stability and improves osseointegration of initially unstable implants
Aims: To develop an early implant instability murine model and explore the use of intermittent parathyroid hormone (iPTH) treatment for initially unstable implants. Methods: 3D-printed titanium implants were inserted into an oversized drill-hole in the tibiae of C57Bl/6 mice (n = 54). After implantation, the mice were randomly divided into three treatment groups (phosphate buffered saline (PBS)-control, iPTH, and delayed iPTH). Radiological analysis, micro-CT (µCT), and biomechanical pull-out testing were performed to assess implant loosening, bone formation, and osseointegration. Peri-implant tissue formation and cellular composition were evaluated by histology. Results: iPTH reduced radiological signs of loosening and led to an increase in peri-implant bone formation over the course of four weeks (timepoints: one week, two weeks, and four weeks). Observational histological analysis shows that iPTH prohibits the progression of fibrosis. Delaying iPTH treatment until after onset of peri-implant fibrosis still resulted in enhanced osseointegration and implant stability. Despite initial instability, iPTH increased the mean pull-out strength of the implant from 8.41 N (SD 8.15) in the PBS-control group to 21.49 N (SD 10.45) and 23.68 N (SD 8.99) in the immediate and delayed iPTH groups, respectively. Immediate and delayed iPTH increased mean peri-implant bone volume fraction (BV/TV) to 0.46 (SD 0.07) and 0.34 (SD 0.10), respectively, compared to PBS-control mean BV/TV of 0.23 (SD 0.03) (PBS-control vs immediate iPTH, p < 0.001; PBS-control vs delayed iPTH, p = 0.048; immediate iPTH vs delayed iPTH, p = 0.111). Conclusion: iPTH treatment mediated successful osseointegration and increased bone mechanical strength, despite initial implant instability. Clinically, this suggests that initially unstable implants may be osseointegrated with iPTH treatment. Cite this article: Bone Joint Res 2022;11(5):260–269.
- Open Access
- 27 December 2021
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 6 (3) , e10596
A Subset of Osteosarcoma Bears Markers of CXCL12‐Abundant Reticular Cells
Currently, the cell of origin for osteosarcoma or other primary skeletal tumors is largely unknown. Recent reports identifying specific cell types comprising bone now newly enable investigation of this topic. Specifically, CXC motif chemokine 12 (CXCL12)‐abundant reticular (CAR) cells are a specific skeletal stromal cell type that orchestrate the bone marrow microenvironment through cross‐talk with hematopoietic and endothelial cells and a likely candidate cell of origin for at least a subset of primary skeletal tumors. Here, we analyze osteosarcomas via immunohistochemistry for known markers of CAR cells such as leptin receptor (LEPR), B‐cell factor 3 (EBF3), CXCL12, and platelet‐derived growth factor receptor alpha (PDGFRA). A large proportion of high‐grade tumors expressed LEPR, PDGFRA, and EBF3 but not CXCL12. These data raise the hypothesis that CAR cells are the cell of origin of this osteoblastic osteosarcoma subset, a finding with implications for the cellular oncogenesis of primary osteosarcoma and the development of effective targeted therapies. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
- 27 December 2021
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 6 (3) , e10596
Open AccessA Subset of Osteosarcoma Bears Markers of CXCL12‐Abundant Reticular Cells
Currently, the cell of origin for osteosarcoma or other primary skeletal tumors is largely unknown. Recent reports identifying specific cell types comprising bone now newly enable investigation of this topic. Specifically, CXC motif chemokine 12 (CXCL12)‐abundant reticular (CAR) cells are a specific skeletal stromal cell type that orchestrate the bone marrow microenvironment through cross‐talk with hematopoietic and endothelial cells and a likely candidate cell of origin for at least a subset of primary skeletal tumors. Here, we analyze osteosarcomas via immunohistochemistry for known markers of CAR cells such as leptin receptor (LEPR), B‐cell factor 3 (EBF3), CXCL12, and platelet‐derived growth factor receptor alpha (PDGFRA). A large proportion of high‐grade tumors expressed LEPR, PDGFRA, and EBF3 but not CXCL12. These data raise the hypothesis that CAR cells are the cell of origin of this osteoblastic osteosarcoma subset, a finding with implications for the cellular oncogenesis of primary osteosarcoma and the development of effective targeted therapies. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.